Related Experiment Video

Updated: Apr 21, 2026

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

3.6K

Issues in interpreting the in vivo activity of Aurora-A

Elena Shagisultanova1, Roland L Dunbrack, Erica A Golemis

  • 1Fox Chase Cancer Center, Department of Medical Oncology , Philadelphia, PA 19111 , USA.

Expert Opinion on Therapeutic Targets
|November 12, 2014
PubMed
Abstract

Insights

Small-molecule inhibitors targeting Aurora-A (AURKA) kinase show promise in cancer treatment. Comprehensive analysis of AURKA activity and its partners is crucial for patient stratification and optimizing inhibitor efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Aurora-A (AURKA) kinase is a mitotic regulator overexpressed in cancer, linked to aneuploidy.
  • Small-molecule inhibitors targeting AURKA have demonstrated efficacy in preclinical and clinical studies.
  • Accurate measurement of AURKA kinase activity in tumors is essential for optimizing inhibitor therapy.

Purpose of the Study:

  • To review the molecular mechanisms of Aurora-A kinase activation, both mitotic and non-mitotic.
  • To discuss the interaction of Aurora-A with its regulatory partners.
  • To highlight the need for comprehensive assessment of Aurora-A activity for patient stratification.

Main Methods:

  • Overview of established methods for measuring Aurora-A activity, primarily phospho-antibodies targeting T288.
  • Discussion of recent findings on alternative Aurora-A activation pathways.
  • Examination of the influence of Aurora-A partners on inhibitor efficacy.

Main Results:

  • Aurora-A activation is regulated by multiple mechanisms beyond T288 phosphorylation, including allosteric regulation and phosphorylation at alternative sites (S51, S98).
  • Dephosphorylation at inhibitory sites (S342) also impacts Aurora-A activity.
  • Aurora-A activation occurs in interphase cells, not solely during mitosis.
  • The abundance of Aurora-A partners affects inhibitor activity.

Conclusions:

  • Current methods for measuring Aurora-A activity may not fully capture its regulatory complexity.
  • A comprehensive analysis of Aurora-A activity and its partners is necessary.
  • This approach will enable better patient stratification for Aurora-A inhibitor therapy.
Keywords:
AURKAAurora-ANEDD9PAKTPX2allosteric activationcancerphosphorylationtargeted therapy

More Related Videos

Visualizing Protein Kinase A Activity In Head-fixed Behaving Mice Using In Vivo Two-photon Fluorescence Lifetime Imaging Microscopy10:41

Visualizing Protein Kinase A Activity In Head-fixed Behaving Mice Using In Vivo Two-photon Fluorescence Lifetime Imaging Microscopy

Published on: June 7, 2019

9.2K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.7K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.8K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
9.5K